PSMA-1007 clinical trials
How each study uses PSMA-1007 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the PSMA-1007 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- [18F]PSMA-1007
- 3
Studies by the year they started
4 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2021 | 2 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 2
ABX advanced biochemical compounds GmbH (2) · Glenn Bauman (1) · Irene Burger (1)
Often tested with
Tested in the same studies.
PSMA-11 (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test PSMA-1007, phase 3 first.
- Mar 2027Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate CancerPhase 3 · ABX advanced biochemical compounds GmbH
Studies
Open first, then newest update. How each study uses PSMA-1007 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate CancerRecruitingPhase 3ABX advanced biochemical compounds GmbHNCT06122584Written as [18F]PSMA-1007How we know
- Multi-modality Imaging (PCa) Using Sodium MRI and PSMA PET in Men Pre-prostatectomyCompletedPhase 2Glenn BaumanNCT04053842Written as [18F]PSMA-1007 InjectionHow we know
- Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate CancerCompletedPhase 3ABX advanced biochemical compounds GmbHNCT04742361Written as [18F]PSMA-1007How we know
- Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Guided Biopsy in Men With Elevated PSACompletedNot applicableIrene BurgerNCT03187990Written as [18F]PSMA-1007How we know